Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate-to-severe chronic plaque psoriasis.

Poulin, Y; Ramon, M; Rosoph, L; Weisman, J; Mendelsohn, A M; Parno, J; Rozzo, S J; Lee, P

Poulin, Y; Ramon, M; Rosoph, L; Weisman, J; Mendelsohn, A M; Parno, J; Rozzo, S J; Lee, P.

Affiliation

Poulin Y; Université Laval, Hôpital Hôtel-Dieu de Québec, Québec City, QC, Canada.
Ramon M; Centre de Recherche Dermatologique du Québec métropolitain, Québec City, QC, Canada.
Rosoph L; Department of Dermatology, Rambam Health Campus, Haifa, Israel.
Weisman J; North Bay Dermatology Centre, North Bay, ON, Canada.
Mendelsohn AM; Medical Dermatology Specialists, Inc., Atlanta, GA, USA.
Parno J; Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA.
Rozzo SJ; Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA.
Lee P; Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA.

J Eur Acad Dermatol Venereol ; 34(7): 1500-1509, 2020 Jul.

Article in En | MEDLINE | ID: mdl-31919889

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Antibodies, Monoclonal, Humanized Type of study: Clinical_trials Limits: Humans Language: En Journal: J Eur Acad Dermatol Venereol Journal subject: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Year: 2020 Document type: Article Affiliation country: Canadá

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google